Ribomunyl from the group of immunostimulating preparations contains ribosomal fractions of bacterial strains (Klebsiella pneumoniae, Diplococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and membra- nous fractions of proteoglycans of Klebsiella pneumoniae as adjuvans). After evaluation of the therapeutic effect, effectiveness and safety of Ribomunyl in reccurent diseases of the respiratory and ENT tract in children the authors implemented an international prospective open multicentre study in 39 departments in the Czech and Slovak Republic. The study was started in autumn (October 1997) and terminated in spring (March 1998) to cover the most exposed winter period as regards infections. In the submitted study the patients were followed up for 6 months. A total of 739 children aged 1 to 12 years in 39 centres were included. The most frequent diagnoses on account of which the children were included in the study were rhinopharyngitis and bronchitis. From the total number of 739 children included in the study 503 (68%) children had never immunostimulation treatment in the past. The remaining 236 (32%) children used in the past some immunostimulating preparation. From the total number of 739 children the drug was poorly tolerated by 16 after three months and by 10 after 6 months. They complained of nausea and dyspepsia. The drug was discontinued only in one patient. The authors proved a reduced use of antibiotics in the investigated inflammatory attacks of the disease, episodes if present had a much milder course, the children were usually afebrile. Complications of inflammatory episodes declined significantly. The tolerance of the administered Ribomunyl was satisfactory, only 2% children from the total number reported complaints such as nausea and dyspepsia.

        Key words: Ribomunyl, multicentre study, reccurent disease, children